- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9-, 30-, and 60-fold higher than ...
The MarketWatch News Department was not involved in the creation of this content. Nashville, TN, Nov. 25, 2025 (GLOBE NEWSWIRE) -- TailorCare, a leading provider of value-based specialty care ...
Nashville, TN, Nov. 25, 2025 (GLOBE NEWSWIRE) -- TailorCare, a leading provider of value-based specialty care solutions for musculoskeletal (MSK) health, announced the formation of its AI Advisory ...
- Using Ascletis' proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly ...
The Alexandria Sportsman’s Club October Athletes of the Month from all four City of Alexandria High Schools will be honored as the tradition continues at the ASC Washington Commanders Night Oct. 16 at ...
You note that the rejection of Replimune’s metastatic-melanoma immunotherapy, RP1, harms patients and stunts pharmaceutical development (“The Spin Doctors at the FDA,” Review & Outlook, Oct. 28) It ...
-In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately 15 days, 3-fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing ...
I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Rocket Pharmaceuticals (RCKT). The reason why I believe it is important to go over this ...
Ascletis Pharma Inc. has selected ASC-35, a once-monthly, subcutaneously administered GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) dual peptide agonist, as a clinical development candidate. Ascletis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback